SG11201406837TA - Biomarkers for iap inhibitor therapy - Google Patents

Biomarkers for iap inhibitor therapy

Info

Publication number
SG11201406837TA
SG11201406837TA SG11201406837TA SG11201406837TA SG11201406837TA SG 11201406837T A SG11201406837T A SG 11201406837TA SG 11201406837T A SG11201406837T A SG 11201406837TA SG 11201406837T A SG11201406837T A SG 11201406837TA SG 11201406837T A SG11201406837T A SG 11201406837TA
Authority
SG
Singapore
Prior art keywords
biomarkers
inhibitor therapy
iap inhibitor
iap
therapy
Prior art date
Application number
SG11201406837TA
Inventor
John Scott Cameron
Caroline Emery
Dale Porter
Douglas Robinson
Kavitha Venkatesan
Li Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201406837TA publication Critical patent/SG11201406837TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays
SG11201406837TA 2012-05-04 2013-05-03 Biomarkers for iap inhibitor therapy SG11201406837TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642899P 2012-05-04 2012-05-04
PCT/US2013/039362 WO2013166344A1 (en) 2012-05-04 2013-05-03 Biomarkers for iap inhibitor therapy

Publications (1)

Publication Number Publication Date
SG11201406837TA true SG11201406837TA (en) 2014-11-27

Family

ID=48407833

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406837TA SG11201406837TA (en) 2012-05-04 2013-05-03 Biomarkers for iap inhibitor therapy

Country Status (20)

Country Link
US (1) US9353419B2 (en)
EP (1) EP2844764B1 (en)
JP (1) JP6513019B2 (en)
KR (1) KR20150011822A (en)
CN (1) CN104284988A (en)
AU (1) AU2013256182A1 (en)
BR (1) BR112014027413A2 (en)
CA (1) CA2871995A1 (en)
CL (1) CL2014002976A1 (en)
ES (1) ES2593046T3 (en)
HK (1) HK1202589A1 (en)
IL (1) IL235315A0 (en)
MA (1) MA37475A1 (en)
MX (1) MX2014013429A (en)
PH (1) PH12014502461A1 (en)
RU (1) RU2014148779A (en)
SG (1) SG11201406837TA (en)
TN (1) TN2014000443A1 (en)
TW (1) TW201347760A (en)
WO (1) WO2013166344A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
CA2970525A1 (en) 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
KR20200081417A (en) * 2017-11-01 2020-07-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 New agents targeting apoptosis inhibitor proteins

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
ES2318167T3 (en) 2002-07-15 2009-05-01 The Trustees Of Princeton University IAP UNION COMPOUNDS.
JP2007522116A (en) 2004-01-16 2007-08-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Conformationally constrained Smac mimetics and uses thereof
CA2553871A1 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
US7345081B2 (en) 2004-03-23 2008-03-18 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
RU2425838C2 (en) 2004-04-07 2011-08-10 Новартис Аг Iap inhibitors
PL1778718T3 (en) 2004-07-02 2015-03-31 Genentech Inc Inhibitors of iap
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
US20100190688A1 (en) 2004-07-12 2010-07-29 Bin Chao Tetrapeptide analogs
ES2475207T3 (en) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation IAP binding compounds
NZ589670A (en) 2004-12-20 2013-01-25 Genentech Inc Pyrrolidine inhibitors of iap
EP1960551A2 (en) * 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
CA2665838A1 (en) * 2006-10-19 2008-05-15 Novartis Ag Organic compounds
CN101529254A (en) * 2006-10-19 2009-09-09 诺瓦提斯公司 Organic compounds
TWI432212B (en) 2007-04-30 2014-04-01 Genentech Inc Inhibitors of iap
EP2382465A1 (en) * 2009-01-29 2011-11-02 Otto-von-Guericke-Universität Magdeburg Method of determining sensitivity of human or non-human animal cells to an iap antagonist
JP2012517238A (en) * 2009-02-11 2012-08-02 カリス エムピーアイ インコーポレイテッド Molecular profiling of tumors
EP2478358A1 (en) * 2009-09-18 2012-07-25 Novartis AG Biomarkers for iap inhibitor compounds
CN101956014B (en) 2010-09-30 2014-05-28 中山大学 Kit for detecting 7 genetic markers of peripheral blood in early diagnosis of nasopharyngeal darcinoma

Also Published As

Publication number Publication date
AU2013256182A1 (en) 2014-11-13
BR112014027413A2 (en) 2017-06-27
EP2844764A1 (en) 2015-03-11
CA2871995A1 (en) 2013-11-07
EP2844764B1 (en) 2016-06-22
US9353419B2 (en) 2016-05-31
CL2014002976A1 (en) 2015-02-13
HK1202589A1 (en) 2015-10-02
RU2014148779A (en) 2016-06-27
CN104284988A (en) 2015-01-14
MX2014013429A (en) 2014-12-08
US20150105434A1 (en) 2015-04-16
WO2013166344A1 (en) 2013-11-07
PH12014502461A1 (en) 2014-12-22
JP6513019B2 (en) 2019-05-15
JP2015523056A (en) 2015-08-13
ES2593046T3 (en) 2016-12-05
IL235315A0 (en) 2014-12-31
TN2014000443A1 (en) 2016-03-30
MA37475A1 (en) 2016-05-31
KR20150011822A (en) 2015-02-02
TW201347760A (en) 2013-12-01

Similar Documents

Publication Publication Date Title
HK1211921A1 (en) Inhibitor compounds
IL229336A (en) Biomarkers for hedgehog inhibitor therapy
GB201213567D0 (en) Biomarkers
GB201211982D0 (en) Biomarker
HK1203949A1 (en) Inhibitors of iap iap
HK1209422A1 (en) Fbxo3 inhibitors fbxo3
EP2828282A4 (en) Biomarkers
GB201210565D0 (en) Biomarkers
HK1202589A1 (en) Biomarkers for iap inhibitor therapy iap
GB201211019D0 (en) Inhibitor compounds
GB201209802D0 (en) Biomarker
GB201202944D0 (en) Biomarker
GB201204391D0 (en) Biomarker
GB201200507D0 (en) Biomarker
ZA201407646B (en) Biomarkers for iap inhibitor therapy
GB201216562D0 (en) Biomarker
GB201214806D0 (en) Biomarker
GB201211229D0 (en) Biomarker
GB201209785D0 (en) Biomarker